These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26716509)

  • 1. Integrative bioinformatic analyses of an oncogenomic profile reveal the biology of endometrial cancer and guide drug discovery.
    Wong HS; Juan YS; Wu MS; Zhang YF; Hsu YW; Chen HH; Liu WM; Chang WC
    Oncotarget; 2016 Feb; 7(5):5909-23. PubMed ID: 26716509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles.
    Wang L; Li F; Sheng J; Wong ST
    BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S6. PubMed ID: 26099165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients: a bioinformatic and clinical study and the therapeutic implication.
    He S; Zeng S; Zhou ZW; He ZX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1103-75. PubMed ID: 25733820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ECGene: A Literature-Based Knowledgebase of Endometrial Cancer Genes.
    Zhao M; Liu Y; O'Mara TA
    Hum Mutat; 2016 Apr; 37(4):337-43. PubMed ID: 26699919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational Drug Repurposing Based on a Recommendation System and Drug-Drug Functional Pathway Similarity.
    Shao M; Jiang L; Meng Z; Xu J
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure.
    Tokheim C; Bhattacharya R; Niknafs N; Gygax DM; Kim R; Ryan M; Masica DL; Karchin R
    Cancer Res; 2016 Jul; 76(13):3719-31. PubMed ID: 27197156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of genome-wide association studies for cancer research and drug repositioning.
    Zhang J; Jiang K; Lv L; Wang H; Shen Z; Gao Z; Wang B; Yang Y; Ye Y; Wang S
    PLoS One; 2015; 10(3):e0116477. PubMed ID: 25803826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PATIENT-SPECIFIC DATA FUSION FOR CANCER STRATIFICATION AND PERSONALISED TREATMENT.
    Gligorijević V; Malod-Dognin N; Pržulj N
    Pac Symp Biocomput; 2016; 21():321-32. PubMed ID: 26776197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation status coupled with RNA-sequencing data can efficiently identify important non-significantly mutated genes serving as diagnostic biomarkers of endometrial cancer.
    Liu K; He L; Liu Z; Xu J; Liu Y; Kuang Q; Wen Z; Li M
    BMC Bioinformatics; 2017 Dec; 18(Suppl 14):472. PubMed ID: 29297280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumour heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification: a descriptive study.
    Cuevas D; Velasco A; Vaquero M; Santacana M; Gatius S; Eritja N; Estaran E; Matias-Guiu X
    Histopathology; 2020 Feb; 76(3):447-460. PubMed ID: 31550396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational functional genomics-based approaches in analgesic drug discovery and repurposing.
    Lippmann C; Kringel D; Ultsch A; Lötsch J
    Pharmacogenomics; 2018 Jun; 19(9):783-797. PubMed ID: 29792109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative cancer pharmacogenomics to establish drug mechanism of action: drug repurposing.
    El-Hachem N; Ba-Alawi W; Smith I; Mer AS; Haibe-Kains B
    Pharmacogenomics; 2017 Nov; 18(16):1469-1472. PubMed ID: 29057710
    [No Abstract]   [Full Text] [Related]  

  • 14. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.
    Cheng F; Hong H; Yang S; Wei Y
    Brief Bioinform; 2017 Jul; 18(4):682-697. PubMed ID: 27296652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.
    Covell DG
    PLoS One; 2015; 10(7):e0127433. PubMed ID: 26132924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.
    Cha S; Lee J; Shin JY; Kim JY; Sim SH; Keam B; Kim TM; Kim DW; Heo DS; Lee SH; Kim JI
    BMC Cancer; 2016 Feb; 16():170. PubMed ID: 26925973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining a mutational signature for endometrial cancer screening and early detection.
    Costas L; Palomero L; Benavente Y; Guardiola M; Frias-Gomez J; Pavón MÁ; Climent M; Martinez JM; Barahona M; Salinas M; Pineda M; Bianchi I; Reventós J; Capellà G; Diaz M; Vidal A; Piulats JM; Ponce J; Brunet J; Bosch FX; Matias-Guiu X; Alemany L; de Sanjosé S; Aytés Á;
    Cancer Epidemiol; 2019 Aug; 61():129-132. PubMed ID: 31238232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses.
    McAlpine J; Leon-Castillo A; Bosse T
    J Pathol; 2018 Apr; 244(5):538-549. PubMed ID: 29344951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
    Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
    Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Computational Functional Genomics in Drug Discovery and Repurposing for Analgesic Indications.
    Lötsch J; Kringel D
    Clin Pharmacol Ther; 2018 Jun; 103(6):975-978. PubMed ID: 29350398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.